Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2123 Target Snapshot

P2Y purinoceptor 4 · SINGLE PROTEIN · Homo sapiens

440Compounds
88Assays
2Approved Drugs
325.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

P2Y purinoceptor 4 shows late clinical disease relevance led by dry eye syndrome. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P51582. Start with dry eye syndrome, then reuse UniProt P51582 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with dry eye syndrome, then reuse UniProt P51582 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
dry eye syndrome

P2Y purinoceptor 4 shows late clinical disease relevance led by dry eye syndrome. 1 linked drug remains visible in the same block.

Start review with dry eye syndrome because it currently carries late clinical support. Linked drugs include DIQUAFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats P2Y purinoceptor 4 as ChEMBL target CHEMBL2123, mapped to UniProt P51582. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
P2Y purinoceptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2123
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P51582
P2Y purinoceptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether P2Y purinoceptor 4 is the right protein anchor across sources, using UniProt P51582 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why dry eye syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelP2Y purinoceptor 4
UniProt AccessionP51582
Component TypeProtein
Sequence Length365 aa

P2Y purinoceptor 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as P2Y purinoceptor 4, mapped to UniProt P51582. Sequence length is 365 aa.

Mapped IDP51582
Review nameP2Y purinoceptor 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

P2Y purinoceptor 4 shows late clinical disease relevance led by dry eye syndrome.

Late clinical Phase III
dry eye syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugDIQUAFOSOL TETRASODIUM
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with dry eye syndrome because it currently carries late clinical support. Linked drugs include DIQUAFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasedry eye syndrome
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
3
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC5094.0
EC50231.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3261372 7.7 EC50 20.0 Preclinical
CHEMBL1767409 7.64 EC50 23.0 Preclinical
CHEMBL1784894 7.64 EC50 23.0 Preclinical
CHEMBL3261369 7.64 EC50 23.0 Preclinical
CHEMBL1198849 7.6 EC50 25.0 Preclinical
CHEMBL336296 7.41 EC50 39.0 Clinical
CHEMBL3261376 7.4 EC50 40.0 Preclinical
CHEMBL3261375 7.33 EC50 47.0 Preclinical
CHEMBL606210 7.31 EC50 49.0 Preclinical
CHEMBL1083764 7.3 EC50 50.0 Preclinical
Distribution

pChEMBL Value Distribution

65
5.0
52
5.5
36
6.0
20
6.5
29
7.0
7
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DIQUAFOSOL TETRASODIUM
CHEMBL1767408
Approved 2010
DIQUAFOSOL
CHEMBL221326
Approved 2010
Assay Landscape

Assay Landscape

88
Total Assays
181
Tested Compounds
2
Assay Types
Functional — 78 assays, 181 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 62 168 5.9
assay format 16 13 6.0
Binding — 10 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 3 6.4
single protein format 5 1 5.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine